Scholarlink

<p>The 2023 update of the European Society of Cardiology guidelines for the management of cardiovascular disease (CVD) in patients with diabetes are designed to guide prevention, early diagnosis, and management of CVD in patients with diabetes and provide recommendations on CVD risk stratification, as well as on screening. This article provides a&#xa0;summary of the key recommendations and a&#xa0;practical approach for cardiologists in the Netherlands to implement these guidelines in daily clinical practice by focusing on recommendations related to type&#xa0;2 diabetes, including a&#xa0;step-by-step scheme for prescription of Sodium-Glucose Transport Protein&#xa0;2 Inhibitors (SGLT2) inhibitors and Glucagon-like peptide‑1 (GLP-1) receptor agonists. These agents can be prescribed in addition to standard care, and independent of glucose control, target HbA1c, or obesity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

2023 European Society of Cardiology guidelines for the management of cardiovascular disease in patients with diabetes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月9日

查看全文
  • Fabrice M. A. C. Martens,
  • Frank L. J. Visseren,
  • Jan Westerink,
  • Ruud F. Spee,
  • El Messaoudi Saloua,
  • Arend Mosterd,
  • Louis M. Handoko,
  • Maarten J. G. Leening,
  • Tjeerd J. Römer,
  • Andries Slootweg,
  • Arianne C. van Bon,
  • Martin E. W. Hemels

摘要

The 2023 update of the European Society of Cardiology guidelines for the management of cardiovascular disease (CVD) in patients with diabetes are designed to guide prevention, early diagnosis, and management of CVD in patients with diabetes and provide recommendations on CVD risk stratification, as well as on screening. This article provides a summary of the key recommendations and a practical approach for cardiologists in the Netherlands to implement these guidelines in daily clinical practice by focusing on recommendations related to type 2 diabetes, including a step-by-step scheme for prescription of Sodium-Glucose Transport Protein 2 Inhibitors (SGLT2) inhibitors and Glucagon-like peptide‑1 (GLP-1) receptor agonists. These agents can be prescribed in addition to standard care, and independent of glucose control, target HbA1c, or obesity.